-

GE HealthCare announces cash dividend for fourth quarter of 2025

CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the fourth quarter of 2025 payable on February 13, 2026, to all shareholders of record as of January 9, 2026.

About GE HealthCare Technologies Inc.
GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient’s journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™.

Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.

Contacts

Investor Relations Contact:
Carolynne Borders
+1 631 662 4317
carolynne.borders@gehealthcare.com

Media Contact:
Jennifer Fox
+ 1 414 530 3027
jennifer.r.fox@gehealthcare.com

Industry:

GE HealthCare Technologies Inc.

NASDAQ:GEHC
Release Versions
English

Contacts

Investor Relations Contact:
Carolynne Borders
+1 631 662 4317
carolynne.borders@gehealthcare.com

Media Contact:
Jennifer Fox
+ 1 414 530 3027
jennifer.r.fox@gehealthcare.com

More News From GE HealthCare Technologies Inc.

GE HealthCare unveils Pristina Recon DL for mammography – deep learning image reconstruction technology delivering clearer image quality

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) announced today that it has received FDA Premarket Authorization for Pristina Recon DL, an advanced 3D mammography image reconstruction technology. Powered by deep learning, Pristina Recon DL sets a new standard in image definition and sharpness. Breast cancer remains one of the most common cancers among women, with one in eight expected to face a diagnosis in their lifetime2 and an estimated 1.1 million breast cancer–related deaths project...

GE HealthCare introduces Genesis™ Radiology Workspace: a cloud-first solution with a goal for smarter, faster diagnosis

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) announced the introduction of Genesis™ Radiology Workspace, a next-generation solution designed to transform radiology workflows, unify the user experience, and empower radiologists with great efficiency and precision. At the center of this innovation is Genesis™ View, 510(k) pending2, a powerful new viewer designed to be a fast diagnostic, zero-footprint viewer – streamlining radiology workflows with the intent to enhance patient care whil...

GE HealthCare’s Photonova™ Spectra with Deep Silicon reimagines photon-counting CT to see more, know more and achieve more

CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced the submission of a 510(k) to the U.S. FDA seeking clearance for Photonova™ Spectra,i its new photon-counting computed tomography (PCCT) system with advanced AI algorithmsii – marking a major milestone in the company’s decades-long history of CT innovation. Built on GE HealthCare’s proprietary Deep Silicon detector technology, Photonova Spectra is designed to deliver remarkable spectral and spatial resolution for ultra-high-definition (UHD...
Back to Newsroom